Biohealth Innovation
July 8 - 9, 2015, Boston, MA, USA
The first ever Organ-on-a-Chip World Congress focuses on Organ-on-a-Chip technology, Biofabrication and 3D-Bioprinting in the life sciences. The conference will be held on 8-9 July 2015 in Boston, organized by Selectbio.
MIMETAS is corporate sponsor of this inaugural conference.
Oral Presentation Abstract Submission Deadline: February 27, 2015
Poster Submission Deadline: June 30, 2015
Maarssen, the Netherlands, 14 June 2013 - MIMETAS was awarded the prestigious LifeSciences@Work award during yesterdays' Dutch Life Sciences SME Event. 75 recently established Life Science companies were invited to compete through an on-line video pitch contest. The video pitches were analyzed by a professional jury, consisting of primarily investors and life science professionals.
MIMETAS today announces the appointment of Herbert L. Heyneker, Ph.D. as Chairman of the Board of Directors. Dr. Heyneker will be supporting MIMETAS in her mission to develop high-throughput Organ-on-a-Chip products for predictive therapy testing.
"Organ-on-a-Chip technology is extremely hot in the United States today. But none of the technologies I've seen so far comes even close to the level of elegance and sophistication that MIMETAS is offering." says Herb Heyneker, who is based in the San Francisco Bay area. "I am strongly convinced that MIMETAS technology has the potential to create a revolution in medicine development and therapy selection. [...]"
MIMETAS' co-founder Paul Vulto has won the Audience Award and the runner up Jury Award for Best Proposition at the International Conference on the Commercialisation of Micro- and Nanosystems (COMS). The jury, which included serial entrepreneur Steven Walsh and Silicon Valley entrepreneur Janusz Bryzek, called the MIMETAS proposition a technology that will change the world, having the potential to grow into a billion-dollar company.
The UK-based National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) has awarded MIMETAS with £100k in the NephroTube Crack-it Challenge, sponsored by GlaxoSmithKline, Pfizer and Roche.
The NephroTube Crack-it Challenge aims to develop a microfluidic renal model predicting renal toxicity during pre-clinical development. In collaboration with the UMCN Pharmacology-Toxicology Department and the Swiss FHNW, MIMETAS will develop a kidney-on-a-chip by combining its OrganoPlate™ 3D-culturing technology with the human renal cell line ciPTEC™.
MIMETAS and BHI created a U.S. subsidiary of MIMETAS to access the clinical, regulatory and scientific resources available in Central Maryland and to access the U.S. marketplace, the largest life sciences market in the world.
"We're very pleased to add Todd to the MIMETAS team," said Jos Joore, Ph.D., Chief Business Officer of MIMETAS. "Todd couples a vast experience in business creation with a profound understanding of biology and disease mechanisms. Most importantly, Todd shares our sense of urgency around enabling better medical treatment by using more predictive cell culture models."
MIMETAS and Galapagos will collaborate to develop miniaturized 3D cell culture models that mimic specific aspects of human diseases. These models will be applied to the identification and improvement of novel compounds. Dr. Richard Janssen, Senior Director of Target Discovery at Galapagos, states: "The MIMETAS platform is the first to combine organ-on-a-chip technology with our high throughput screening of primary human cells. As we see it, OrganoPlates™ make 3D culture as straightforward as traditional cell culture."
MIMETAS is part of Medical Delta: the consortium of top life sciences and medical technology partners in the Netherlands. Medical Delta is a research, sales and logistics driven life sciences and medical technology cluster situated in the economic heart of the Netherlands, between Amsterdam Schiphol Airport and the Port of Rotterdam. In this Leiden -- Delft -- Rotterdam region, top-ranked universities and medical centers work together with industry and government to provide a dynamic environment for innovative spinoffs and international companies. With thanks to Roel Kamerling.